BeOne Medicines Lymphoma Drug Gets FDA Priority Review

Tuesday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Merck and Arvinas Holding are rallying, while stocks like SanDisk and Tesla are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers (Market Cap:$200B and above)

• Merck & Co (MRK); Merck’s WINREVAIR shows positive results in heart failure study: +4.39%
• Nvidia Corp (NVDA); Global supercomputing centers adopt NVIDIA NVQLink for quantum computing: -2.46%
• United Health Group (UNH); Former FDA commissioner Scott Gottlieb joins UnitedHealth board: -2.58%
• Microsoft Corp (MSFT); Microsoft stock downgraded by Rothschild Redburn on AI economics concerns: -2.77%
• Tesla Motors (TSLA): -3.0%
• Amazon Com Inc (AMZN); Amazon (AMZN) sets size of U.S. dollar bond offering at $15B - Bloomberg: -3.14%
• Palantir Technologies Inc (PLTR): -1.76%
• Adv Micro Device (; AMD, Eviden to build Europe’s second exascale supercomputer: -5.13%
• Micron Tech (MU): -5.42%
• Home Depot (HD): -3.42%

Large-Cap Stock Movers (Market Cap:$10B-$200B)

• SanDisk Corp-Exch (SNDK): -9.99%
• Klarna (KLAR); Klarna posts record Q3 revenue, expects first billion-dollar quarter: -8.79%
• Amer Sports A (AS); Amer Sports soars 9% as strong Salomon, Arc’teryx sales drive Q3 beat: +7.9%
• Western Digital (WDC): -4.87%
• Pinduoduo (PDD); Pinduoduo shares fall 4% after missing Q3 expectations as revenue growth slows: -5.53%
• Fermi America LLC (FRMI): -4.9%
• Medtronic (MDT): +4.86%
• ProShares Trust UltraPro QQQ (TQQQ): -3.83%
• BeiGene (ONC): -4.16%
• GS Acquisition A (VRT): -3.06%

Mid-Cap Stock Movers (Market Cap:$2B-$10B)

• Diginex Inc (DGNX); Diginex and EVIDENT form alliance to enhance tokenized asset ESG data: +11.26%
• Social Capital Hedosophia Hold II (OPEN): -6.66%
• Grail (GRAL): -8.28%
• DAQQ New Energy Corp (DQ): -7.25%
• Figure Technology Solutions Ltd (FIGR); Figure files for blockchain-native stock offering: -8.62%
• PACS (: -8.47%
• Netskope Inc (NTSK): -6.36%
• Solaris Oilfield Infrastructure (SEI): -7.39%
• Bellring Brands LLC (BRBR): -0.69%
• NVDL (NVDL): -4.77%

Small-Cap Stock Movers (Market Cap:$300M-$2B)

• Olema Pharmaceuticals Inc (OLMA): +133.91%
• Energizer Hldgs (ENR); Energizer shares tumble 15% as Q4 earnings miss overshadows revenue beat: -19.66%
• Alpha Technology (ATGL): -21.4%
• Globe Specialty M (GSM): +18.32%
• Arvinas Holding (ARVN): +20.84%
• Adagio Therapeutics (IVVD); Invivyd prices public offering of common stock at $2.50 per share: -13.2%
• i3 Verticals (IIIV): -10.77%
• MUU (MUU): -11.02%
• AMDL (AMDL): -10.19%
• UVIX (UVIX): +9.39%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- BeOne Medicines AG (NASDAQ:ONC) stock rose 4.2% on Monday after the global oncology company announced positive top-line results from a Phase 3 trial evaluating its HER2-targeted bispecific antibody ZIIHERA in combination with chemotherapy for gastroesophageal cancer.

The HERIZON-GEA-01 trial showed that ZIIHERA (zanidatamab) plus chemotherapy, with or without the PD-1 inhibitor TEVIMBRA (tislelizumab), demonstrated "clinically meaningful and highly statistically significant improvements" in progression-free survival compared to the control arm of trastuzumab plus chemotherapy.

Additionally, the ZIIHERA plus TEVIMBRA and chemotherapy combination showed statistically significant improvements in overall survival. The ZIIHERA plus chemotherapy arm also demonstrated a "clinically meaningful effect with a strong trend toward statistical significance" for overall survival compared to the control arm.

The trial is ongoing with an additional planned overall survival interim analysis for ZIIHERA plus chemotherapy expected in mid-2026.

"These results represent meaningful progress for a patient community in urgent need of new treatment options," said Mark Lanasa, Chief Medical Officer for Solid Tumors at BeOne. "With the high incidence of GEA across many regions where we hold rights to ZIIHERA, we have the opportunity to deliver a major advancement for patients in an area of high unmet need."

The company reported that the safety profile of the treatment combinations was generally consistent with the known safety profiles of each agent, with no new safety signals observed.

BeOne plans to submit the data for presentation at a major medical meeting in the first quarter of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.